A- A A+

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. 

Englund, A., Oliver, D., Chesney, E. et al.

Neuropsychopharmacol. (2022). doi.org/10.1038/s41386-022-01478-z


Validity of the Single-Item Screen-Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care. 

Matson TE, Lapham GT, Bobb JF, Oliver M, Hallgren KA, Williams EC, Bradley KA. 

JAMA Netw Open. 2022 Nov 1;5(11):e2239772. doi: 10.1001/jamanetworkopen.2022.39772. PMID: 36318205.


Impacts of recreational cannabis legalization on cannabis use: a longitudinal discordant twin study.

Zellers, SM, Ross, JM, Saunders, GRB, Ellingson, JM, Anderson, JE, Corley, RP, et al. 

Addiction. 2022. doi.org/10.1111/add.16016


„Die Gesundheitsrisiken reduzieren sich auf dem legalen Markt“

Berlin – Abgeordnete des Gesundheitsausschusses im Bundestag haben sich bei einer Delegationsreise nach Kanada und in die Vereinigten Staaten vom 10. bis 17. September rund um Fragen zur Legalisierung von Can­nabis informiert. Im Mittelpunkt standen die Erfahrungen der kanadischen Provinz Ontario und des US-Bun­desstaates Kalifornien. In Kanada ist der Gebrauch von Cannabis seit 2018 legal, Kalifornien hatte diesen Schritt bereits 2016 unternommen.

(…) Fünf Fragen an Kirsten Kappert-Gonther (Grüne), amtierende Vorsitzende des Gesundheitsausschusses. (aerzteblatt.de, 25.09.2022)


Harm reduction interventions as a potential solution to managing cannabis use in people with psychosis: A call for a paradigm shift.

Coronado-Montoya S, Tra C, Jutras-Aswad D. 

Int J Drug Policy. 2022 Aug 1;108:103814. doi: 10.1016/j.drugpo.2022.103814. Epub ahead of print. PMID: 35926338.


Can cannabis kill? Characteristics of deaths following cannabis use in England (1998–2020). 

Rock KL, Englund A, Morley S, Rice K, Copeland CS. 

Journal of Psychopharmacology. 2022;0(0). doi:10.1177/02698811221115760


Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis. 

Schoeler T, Ferris J, Winstock AR. 

Transl Psychiatry. 2022 Sep 6;12(1):369. doi: 10.1038/s41398-022-02112-8. PMID: 36068202; PMCID: PMC9448725.


Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department. 

Razban M, Exadaktylos AK, Santa VD, Heymann EP. 

Int J Emerg Med. 2022 Sep 8;15(1):45. doi: 10.1186/s12245-022-00446-0. PMID: 36076180; PMCID: PMC9454163.


Cannabis use and public health: time for a comprehensive harm-to-others framework

Fischer, Benedikt et al.

The Lancet Public Health, Volume 7, Issue 10, e808 - e809 


Edible Cannabis Legalization and Unintentional Poisonings in Children

Canadian data show that legalization of cannabis for adults has been associated with increased hospitalizations for unintentional cannabis poisoning in children, mostly after legalization of cannabis edibles.

August 25, 2022, N Engl J Med 2022; 387:757-759, DOI: 10.1056/NEJMc2207661


Deutscher Verkehrsgerichtstag empfiehlt Erhöhung des THC-Grenzwerts

Goslar – Der Deutsche Verkehrsgerichtstag hat dem Gesetzgeber eine Erhöhung des THC-Grenzwerts im Stra­ßenverkehr empfohlen. Der derzeit angewandte Grenzwert solle „angemessen“ heraufgesetzt werden, teilte das Gremium heute in Goslar mit. Eine konkrete Zahl wurde nicht genannt. (aerzteblatt.de, 19.09.2022)


Estimating the effects of legalizing recreational cannabis on newly incident cannabis use.

Montgomery BW, Roberts MH, Margerison CE, Anthony JC (2022) 

PLoS ONE 17(7): e0271720. doi.org/10.1371/journal.pone.0271720


Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016–2019,

Tracy A. Klein, Julia A. Dilley, Janessa M. Graves & Erica L. Liebelt (2022)

Clinical Toxicology, DOI: 10.1080/15563650.2022.2099887


Association of cannabis potency with mental ill health and addiction: a systematic review

Petrilli, Kat et al.

The Lancet Psychiatry, Volume 0, Issue 0 


The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls. 

Lawn W, Mokrysz C, Lees R, Trinci K, Petrilli K, Skumlien M, Borissova A, Ofori S, Bird C, Jones G, Bloomfield MA, Das RK, Wall MB, Freeman TP, Curran HV. 

J Psychopharmacol. 2022 Jun 30:2698811221108956. doi: 10.1177/02698811221108956. Epub ahead of print. PMID: 35772419.


High-strength cannabis linked to addiction and mental health problems

Largest ever study into the health effects of different types of cannabis highlights concerns about stronger forms of the drug. (University of Bath, 25.07.2022)


The iCannTookit: a consensus-based, flexible framework for measuring contemporary cannabis use. 

Lorenzetti, V., Hindocha, C., Petrilli, K., Griffiths, P., Brown, J., Castillo-Carniglia, Á., Caulkins, J.P., Englund, A., El Sohly, M.A., Gage, S.H., Groshkova, T., Gual, A., Hammond, D., Lawn, W., López-Pelayo, H., Manthey, J., Mokrysz, C., Liccardo Pacula, R., van Laar, M., Vandrey, R., Wadsworth, E., Winstock, A., Hall, W., Curran, H.V. and Freeman, T.P. (2022), 

Addiction. doi.org/10.1111/add.15956


Knowing Your Limits with Cannabis: A Practical Guide to Assessing Your Cannabis Use 

Canadian Centre on Substance Use and Addiction, Kanada, 2022

Helps people reflect on their cannabis use patterns while providing tips and strategies to encourage lower-risk behaviours to reduce harm. Individuals can use this independently or with the support of healthcare, mental health or addiction service providers.


The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya. 

Ngarachu EW, Kiburi SK, Owiti FR, Kangethe R. 

Subst Abuse Treat Prev Policy. 2022 Feb 15;17(1):12. doi: 10.1186/s13011-022-00437-7. PMID: 35168646; PMCID: PMC8845270.


Clinical management of cannabis withdrawal. 

Connor, JP, Stjepanović, D, Budney, AJ, Le Foll, B, Hall, WD. 

Addiction. 2022; 1– 21. doi.org/10.1111/add.15743


Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”

Suhas Ganesh and Deepak Cyril D’Souza

American Journal of Psychiatry 2022 179:1, 8-10 


Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. 

Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Pacula RL, Rehm J, Room R, Brink WVD, Hall W. 

Int J Drug Policy. 2021 Aug 28:103381. doi: 10.1016/j.drugpo.2021.103381. Epub ahead of print. PMID: 34465496.


Cannabis may contain heavy metals and affect consumer health, study finds

Research team proposes strategies for growers to avoid heavy metals in their cannabis crops. (Penn State University, USA, 14.12.2021)


Systematic review of structural and functional neuroimaging studies of cannabis use in adolescence and emerging adulthood: evidence from 90 studies and 9441 participants. 

Lichenstein, S.D., Manco, N., Cope, L.M. et al.

Neuropsychopharmacol. (2021). doi.org/10.1038/s41386-021-01226-9


Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions

Shamema Nasrin, Christy J.W. Watson, Yadira X Perez-Paramo and Philip Lazarus

Drug Metabolism and Disposition December 2021, 49 (12) 1070-1080; DOI: doi.org/10.1124/dmd.121.000442 


Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites

Shamema Nasrin, Christy J. W. Watson, Keti Bardhi, Gabriela Fort, Gang Chen and Philip Lazarus

Drug Metabolism and Disposition December 2021, 49 (12) 1081-1089; DOI: doi.org/10.1124/dmd.121.000530 


Legalisierung von Cannabis: Risiken für die Gesundheit

Dtsch Arztebl 2021; 118(49): A-2326 / B-1909

Bühring, Petra


The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs. 

Lake S, Kerr T, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, Hayashi K, Milloy MJ. 

Cannabis Cannabinoid Res. 2021 Nov 22. doi: 10.1089/can.2021.0080. Epub ahead of print. PMID: 34813374.



Mu-opioid antagonism in the treatment of cannabis use disorder. 

Kebir O, Laqueille X, Mouaffak F. 

J Psychiatry Neurosci. 2020 Mar 1;45(2):143. doi: 10.1503/jpn.190182. PMID: 32096619; PMCID: PMC7828912. 


Driving under the influence: a multi-center evaluation of vehicular crashes in the era of cannabis legalization. 

Borst JM, Costantini TW, Reilly L, Smith AM, Stabley R, Steele J, Wintz D, Bansal V, Biffl WL, Godat LN. 

Trauma Surg Acute Care Open. 2021 Nov 11;6(1):e000736. doi: 10.1136/tsaco-2021-000736. PMID: 34786487; PMCID: PMC8587622.